Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The double-blind phase III Study 103 compared cobicistat/elvitegravir/emtricitabine/tenofovir DF with atazanavir + ritonavir plus emtricitabine/tenofovir DF in 700 treatment-naive patients[DeJesus 2012b]
- The elvitegravir/cobicistat regimen was noninferior to the atazanavir + ritonavir regimen at Week 48 with 90% vs 87%, respectively, achieving HIV-1 RNA < 50 copies/mL by US FDA snapshot analysis
- Noninferiority has been documented through 144 weeks[Rockstroh 2013b; Clumeck 2014]
- The elvitegravir/cobicistat regimen was noninferior to the atazanavir + ritonavir regimen at Week 48 with 90% vs 87%, respectively, achieving HIV-1 RNA < 50 copies/mL by US FDA snapshot analysis
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content